EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

The impact of vildagliptin as an add‐on therapy on matrix metalloproteinase‐14 levels, liver stiffness and subclinical atherosclerosis in adolescents with type 1 diabetes and non‐alcoholic steatohepatitis: A randomized controlled trial

Zeinab Anwar ElKabbany, Eman Abdel Rahman Ismail iD, Eman Tawfik Hamed, Nancy Samir Elbarbary iD

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15958 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Zeinab Anwar ElKabbany und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Faculty of Medicine, Ain Shams University, Cairo, Egypt. Hauptthemen laut MEDLINE: Vildagliptin, Non-alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 1, Atherosclerosis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 86 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Many patients with type 1 diabetes mellitus (T1DM) met the histological criteria for non‐alcoholic steatohepatitis (NASH), which leads to cardiovascular disease morbidity and mortality. Matrix metalloproteinase‐14 (MMP‐14) is involved in cardiovascular disease and atherosclerosis.

Objectives

To assess the impact of oral dipeptidyl peptidase‐4 inhibitor, vildagliptin, as adjunctive therapy on NASH in adolescents with T1DM and its effect on glycaemic control, MMP‐14 levels and carotid intima media thickness (CIMT).

Methods

Sixty adolescents with T1DM and NASH were randomly assigned to receive oral vildagliptin (50 mg once daily) for 6 months or not. Glycated haemoglobin, lipid profile, hepatic steatosis index, triglyceride glucose (TyG) index and MMP‐14 levels were assessed. Transient elastography with controlled attenuation parameter (CAP) was performed together with measuring CIMT.

Results

By transient elastography, 12 (20%) patients with T1DM with NASH had elevated liver stiffness ≥7 kPa (F2 stage or higher). Baseline MMP‐14 was positively correlated to insulin dose ( p = 0.016), triglycerides and TyG index, CIMT, liver stiffness and CAP levels among the studied patients ( p < 0.001 for all). After 6 months, patients with T1DM on vildagliptin therapy had significantly lower glycated haemoglobin, lipid profile, hepatic steatosis index and TyG index, as well as MMP‐14 ( p < 0.001). CIMT, liver stiffness and CAP were significantly decreased post‐therapy compared with baseline levels and compared with the control group ( p < 0.001). Vildagliptin was safe and well‐tolerated.

Conclusions

Administration of vildagliptin for adolescents with T1DM and NASH improved glycaemic control, dyslipidaemia and MMP‐14 levels and decreased liver stiffness and CIMT; hence, reducing subclinical atherosclerosis and disease progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VildagliptinNon-alcoholic Fatty Liver DiseaseDiabetes Mellitus, Type 1AtherosclerosisDipeptidyl-Peptidase IV InhibitorsMatrix Metalloproteinase 14PyrrolidinesHumansAdolescentMaleFemaleLiverElasticity Imaging TechniquesNitrilesGlycated HemoglobinCarotid Intima-Media ThicknessDrug Therapy, CombinationBlood GlucoseAdamantaneChildHypoglycemic Agents

Stichwörter der Autor:innen

carotid intima media thicknessdipeptidyl peptidase‐4 inhibitordyslipidaemiaglycaemic controlliver stiffnessmatrix metalloproteinase‐14non‐alcoholic steatohepatitistype 1 diabetesvildagliptin

Substanzen

VildagliptinDipeptidyl-Peptidase IV InhibitorsMatrix Metalloproteinase 14PyrrolidinesNitrilesGlycated HemoglobinBlood GlucoseMMP14 protein, humanAdamantaneHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Pediatrics, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
  • Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
  • Department of Pediatrics, Health Insurance Hospitals, Cairo, Egypt.

ORCID-Profile: Eman Abdel Rahman Ismail, Nancy Samir Elbarbary

Zitieren

APA

ElKabbany, Z. A., Ismail, E. A. R., Hamed, E. T., & Elbarbary, N. S. (2024). The impact of vildagliptin as an add‐on therapy on matrix metalloproteinase‐14 levels, liver stiffness and subclinical atherosclerosis in adolescents with type 1 diabetes and non‐alcoholic steatohepatitis: A randomized controlled trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15958

Vancouver

ElKabbany ZA, Ismail EAR, Hamed ET, Elbarbary NS. The impact of vildagliptin as an add‐on therapy on matrix metalloproteinase‐14 levels, liver stiffness and subclinical atherosclerosis in adolescents with type 1 diabetes and non‐alcoholic steatohepatitis: A randomized controlled trial. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15958

BibTeX
@article{ElKabbany2024,
  author = {ElKabbany, Zeinab Anwar and Ismail, Eman Abdel Rahman and Hamed, Eman Tawfik and Elbarbary, Nancy Samir},
  title = {The impact of vildagliptin as an add‐on therapy on matrix metalloproteinase‐14 levels, liver stiffness and subclinical atherosclerosis in adolescents with type 1 diabetes and non‐alcoholic steatohepatitis: A randomized controlled trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15958}
}
Kostenlos starten →